热门出版物 - 学术资源搜索

引用“”的文章Of chloroquine and COVID-19

标题/作者	年份
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu, L Gao, Z Cheng, Q Lu, ... The lancet 395 (10236), 1569-1578	2020
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) W Alhazzani, MH Møller, YM Arabi, M Loeb, MN Gong, E Fan, ... Intensive care medicine 46 (5), 854-887	2020
Compassionate use of remdesivir for patients with severe Covid-19 J Grein, N Ohmagari, D Shin, G Diaz, E Asperges, A Castagna, T Feldt, ... New England Journal of Medicine 382 (24), 2327-2336	2020
COVID‐19 diagnosis and management: a comprehensive review G Pascarella, A Strumia, C Piliego, F Bruno, R Del Buono, F Costa, ... Journal of internal medicine 288 (2), 192-206	2020
Coronavirus disease 2019–COVID-19 K Dhama, S Khan, R Tiwari, S Sircar, S Bhat, YS Malik, KP Singh, ... Clinical microbiology reviews 33 (4), 10.1128/cmr. 00028-20	2020
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial W Tang, Z Cao, M Han, Z Wang, J Chen, W Sun, Y Wu, W Xiao, S Liu, ... bmj 369	2020
The epidemiology, diagnosis and treatment of COVID-19 P Zhai, Y Ding, X Wu, J Long, Y Zhong, Y Li International journal of antimicrobial agents 55 (5), 105955	2020
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331	2020
SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia FJ Díaz-Castrillón, AI Toro-Montoya Medicina & laboratorio 24 (3), 183-205	2021
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries AK Singh, A Singh, A Shaikh, R Singh, A Misra Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14 (3), 241-246	2020
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 M Catanzaro, F Fagiani, M Racchi, E Corsini, S Govoni, C Lanni Signal transduction and targeted therapy 5 (1), 84	2020
The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19 FK Yoshimoto The protein journal 39 (3), 198-216	2020
Coronavirus disease 2019 treatment: a review of early and emerging options EK McCreary, JM Pogue Open forum infectious diseases 7 (4), ofaa105	2020
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 M Hoffmann, K Mösbauer, H Hofmann-Winkler, A Kaul, H Kleine-Weber, ... Nature 585 (7826), 588-590	2020
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ... Nature 585 (7826), 584-587	2020
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 Y Rodríguez, L Novelli, M Rojas, M De Santis, Y Acosta-Ampudia, ... Journal of autoimmunity 114, 102506	2020
Type III interferons disrupt the lung epithelial barrier upon viral recognition A Broggi, S Ghosh, B Sposito, R Spreafico, F Balzarini, A Lo Cascio, ... Science 369 (6504), 706-712	2020
Current epidemiological and clinical features of COVID-19; a global perspective from China H Tu, S Tu, S Gao, A Shao, J Sheng Journal of Infection 81 (1), 1-9	2020
Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis P Sarma, H Kaur, H Kumar, D Mahendru, P Avti, A Bhattacharyya, ... Journal of medical virology 92 (7), 776-785	2020
Can nanotechnology and materials science help the fight against SARS-CoV-2? MC Sportelli, M Izzi, EA Kukushkina, SI Hossain, RA Picca, N Ditaranto, ... Nanomaterials 10 (4), 802	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。